On June 24, 2014, LiveDeal Inc. (NASDAQ:LIVE) (“LiveDeal” or the “Company”), a publicly traded company that operates livedeal.com, a geo-location based mobile marketing platform that enables restaurants to publish “real-time” and “instant offers” to nearby consumers, announces that the company’s efforts has created more than 10,000 offers with nearly 8,000 restaurants across the country, many of which are of recognizable national brands in select markets. LiveDeal Inc (NASDAQ:LIVE), weekly performance is 5.18%. On last trading day company shares ended up $4.47. Analysts mean target price for the company is $1.50. LiveDeal Inc (NASDAQ:LIVE), distance from 50-day simple moving average (SMA50) is 10.34%.
Venaxis Inc (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, announced it will participate in the third annual ICV Company Outreach Summit, being held July 9-10, 2014, in Montauk, New York. Steve Lundy, President and CEO of Venaxis® will be presenting at the conference to investors including representatives from hedge and private equity funds as well as high net worth individuals and family funds. Venaxis Inc (NASDAQ:APPY), advanced 3.96% in last trading session and ended the day on $2.36. AAPY, return on assets is -59.80%. Venaxis Inc (NASDAQ:APPY), quarterly performance is -12.92%.
On June 23, 2014, Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced that it has been selected by HealthTrust as a provider of multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership. Nanosphere, Inc. (NASDAQ:NSPH), shares moved up 3.68% in last trading session and was closed at $1.69, while trading in range of $1.63 – 1.77. Nanosphere, Inc. (NASDAQ:NSPH), year to date (YTD) performance is -26.20%.
Roth Capital assumed coverage on shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT), in a report issued on Friday,TheFlyOnTheWall.com reports. The firm issued a buy rating and a $19.00 target price on the stock. Conatus Pharmaceuticals Inc (NASDAQ:CNAT), ended the last trading day at $9.23. Company weekly volatility is calculated as 8.88% and price to cash ratio as 2.82. Conatus Pharmaceuticals Inc (NASDAQ:CNAT), showed a positive weekly performance of 14.80%.
On June 24, 2014, MeetMe Inc (NASDAQ:MEET), shares are flying after the company set a new record of 15 million user-to-user chats in one day for the first time ever in the company’s history. The daily record was set on Monday, reflecting the increasing popularity and usage of the social discovery company. MeetMe Inc (NASDAQ:MEET), net profit margin is -16.60% and weekly performance is 0.36%. On last trading day company shares ended up $2.77. Analysts mean target price for the company is $4.67. MeetMe Inc (NASDAQ:MEET), distance from 50-day simple moving average (SMA50) is 19.01%.